Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sulkowski

Showing results (351-360 of 408) with videos related to

Pageof 41
Sort By:
Hepatology (Baltimore, Md.)|May 24, 2012
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirinIra M Jacobson, Patrick Marcellin, Stefan Zeuzem, et al.
Alimentary Pharmacology & Therapeutics|January 29, 2015
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevirR K Sterling, A Kuo, V K Rustgi, et al.
Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1Stefan Zeuzem, Mark S Sulkowski, Eric J Lawitz, et al.
Hepatology (Baltimore, Md.)|May 13, 2017
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimenEdward J Gane, Mitchell L Shiffman, Kyle Etzkorn, et al.
Journal of the International AIDS Society|November 14, 2014
Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimensJoseph J Eron, Jay Lalezari, Jihad Slim, et al.
The New England Journal of Medicine|January 17, 2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1Kris V Kowdley, Eric Lawitz, Fred Poordad, et al.
The New England Journal of Medicine|September 16, 2011
Response-guided telaprevir combination treatment for hepatitis C virus infectionKenneth E Sherman, Steven L Flamm, Nezam H Afdhal, et al.
Hepatology (Baltimore, Md.)|October 20, 2012
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trialMark S Sulkowski, Fred Poordad, Michael P Manns, et al.
Gut|July 16, 2016
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET studyTania M Welzel, David R Nelson, Giuseppe Morelli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2014
Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL studyMichael T Melia, Norbert Bräu, Fred Poordad, et al.
Pageof 41

Showing results (351-360 of 408) with videos related to

Sort By:
Pageof 41
Hepatology (Baltimore, Md.)|May 24, 2012
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirinIra M Jacobson, Patrick Marcellin, Stefan Zeuzem, et al.
Alimentary Pharmacology & Therapeutics|January 29, 2015
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevirR K Sterling, A Kuo, V K Rustgi, et al.
Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1Stefan Zeuzem, Mark S Sulkowski, Eric J Lawitz, et al.
Hepatology (Baltimore, Md.)|May 13, 2017
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimenEdward J Gane, Mitchell L Shiffman, Kyle Etzkorn, et al.
Journal of the International AIDS Society|November 14, 2014
Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimensJoseph J Eron, Jay Lalezari, Jihad Slim, et al.
The New England Journal of Medicine|January 17, 2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1Kris V Kowdley, Eric Lawitz, Fred Poordad, et al.
The New England Journal of Medicine|September 16, 2011
Response-guided telaprevir combination treatment for hepatitis C virus infectionKenneth E Sherman, Steven L Flamm, Nezam H Afdhal, et al.
Hepatology (Baltimore, Md.)|October 20, 2012
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trialMark S Sulkowski, Fred Poordad, Michael P Manns, et al.
Gut|July 16, 2016
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET studyTania M Welzel, David R Nelson, Giuseppe Morelli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2014
Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL studyMichael T Melia, Norbert Bräu, Fred Poordad, et al.
Pageof 41